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Abstract
Background: Viral self-replicating sub-genomic replicons represent a powerful tool for studying viral genome
replication, antiviral screening and chimeric vaccine development. Many kinds of flavivirus replicons have been
developed with broad applications.
Findings: The replicon system of JEV live vaccine strain SA14-14-2 was successfully developed in this study. Two
kinds of replicons that express enhanced green fluorescent protein (EGFP) and Renilla luciferase (R.luc) were
constructed under the control of SP6 promoter, respectively. Robust EGFP and R.luc signals could be detected in
the replicon-transfected BHK-21 cells. Furthermore, the potential effects of selected amino acids in the C-terminal of
envelope protein on replication were characterized using the replicon system.
Conclusions: Our results provide a useful platform not only for the study of JEV replication, but also for antiviral
screening and chimeric vaccine development.
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Japanese encephalitis is now recognized as the leading
cause of viral encephalitis in Asian countries, including
China, Japan, Korea, the Philippines, Thailand, and India
[1,2]. Clinical Japanese encephalitis is a severe disease
with a high case fatality rate. World Health Organization
(WHO) estimates that approximately 50,000 cases of
Japanese encephalitis occur each year, resulting in about
10,000 deaths and 15,000 cases of neurological or psy-
chiatric sequelae [3,4]. Japanese encephalitis virus (JEV)
is transmitted in an enzootic cycle between Culex species
mosquitoes and vertebrates, primarily birds with pigs serv-
ing as amplifying hosts. In recent years, JEV has begun to
spread to other geographic areas such as Pakistan and
Australia [5,6]. The geographic expansion and high fatality
rates have drawn increasing attention from the inter-
national public health community [7].
Vaccination has been recognized as the most reliable
and economic measure for protection against Japanese
encephalitis. Currently, three kinds of vaccines are avail-
able: inactivated vaccine produced in mouse-brain or cell
culture and live attenuated vaccine produced on primary
hamster kidney (PHK) cells [8]. The live vaccine (SA14-
14-2) was initially licensed in 1989 in mainland China,
and now exported to most JEV-endemic countries, in-
cluding India, Sri Lanka, Nepal, Thailand and South
Korea under the recommendation of WHO [9]. Large
scale immunizations in more than 300 million children
have well demonstrated its excellent safety and efficacy
profile. Very recently, a novel chimeric JEV live vaccine
based on the genetic background of Yellow fever virus
(YFV) 17D strain was licensed in Australia and is under
active consideration for license in Thailand [10].
JEV belongs to the Flavivirus genus in the family
Flaviviridae together with YFV, dengue virus (DENV),
West Nile virus (WNV), Murray Valley encephalitis
virus (MVEV) and tick-borne encephalitis virus (TBEV).
The genome of JEV is a positive-sense single-stranded
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RNA molecule comprising 10, 976 nucleotides with a
long open reading frame coding for three structural (C,
prM, and E) and seven nonstructural (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, NS5) proteins. The RNA gen-
ome has a type I cap structure at its 50-end and lacks the
poly (A) tail at its 30-end [11].
A viral replicon is a self-replicating sub-genomic viral
RNA originated from viral genome, which contains viral
non-structural genes that are critical for viral genome
replication with structural proteins deleted or replaced
by foreign genes. This non-infectious replicon provides a
valuable platform to study the function and structure
of viral genome RNA, express foreign proteins and
develop novel vaccines. In recent years, many flavi-
virus replicons have been developed, including Kunjin
virus [12], Tick-borne encephalitis virus [13], DENV
[14-17], Yellow fever virus [18,19], and West Nile
virus [20-23].
Figure 1 The schematic representation of JEV replicons constructed in this study. The prM/E coding region was deleted from the genome
of JEV (SA14-14-2) except for the C-terminal amino acid residues of E protein. FMDV-2A was fused downstream of the EGFP and R.luc reporter
genes to ensure cytosolic cleavage of heterologous genes.
Figure 2 Characterization of the JEV replicon. (A) BHK-21 cells transfected with the JEV replicon pJE3Rep were subjected to indirect
immunofluorescence assay (IFA). JEV viral proteins were visualized using NS1- and E-specific mouse monoclonal antibody and stained with
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG at 72 h post-transfection. The green signals represent FITC-positive cells. Viral
RNAs (JEV) and PBS (Mock) were set as controls. (B) RT-PCR targeted at the prM/E genes (Lane 1, 3 and 5) and NS3 genes (Lane 2, 4 and 6). The
amplified products for NS3 and prM/E gene were 1185 and 1208 bp, respectively. Total RNAs were extracted from BHK-21 cells at 72 h post
transfection. Viral RNAs (JEV) and PBS (Mock) were set as controls.
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The reverse genetic system of JEV is greatly hampered
due to the toxicity of JEV cDNA in bacteria. Despite ex-
tensive efforts for many years [24-27], a genetically
stable full-length infectious cDNA clone of JEV was not
obtained until the bacterial artificial chromosome (BAC)
was used as a vector in 2003. Then, several JEV
replicons using the BAC vector were constructed based
on a Korean JEV strain K87P39 to express the foreign
proteins [11]. In this work, we described the preparation
of a sub-genomic replicon derived from JEV attenuated
strain SA14-14-2, as well as, a series of replicons with
Enhanced green fluorescent protein (EGFP) and Renilla
luciferase (R.luc) reporter genes were constructed and
characterized, respectively. These replicons should be
useful for studying many aspects of JEV replication,
expressing foreign proteins and developing new vaccines.
The low-copy pACNR vector and E. coli MC1061 were
employed in our experiments [19,20,28]. All the primers
used in this study are listed in Additional file 1: Table
S1. Firstly, new restriction enzyme sites (XhoI, BspEI,
and AscI) were introduced into the multiple cloning site
of pACNR by fusion PCR with Not I( + )and linker-1(-),
resulting in a new vector named pANCR-L1. The 50-half
(nucleotides [nt] 1 to 3446), 30-1 (3099 to 7299) and 30-2
(7299 to 10976) fragments covering the full-length JEV
SA14-14-2 genomic cDNA were amplified by RT-PCR
using high-fidelity M-MLV reverse transcription poly-
merase (TaKaRa), respectively. Primer pair of F-AscI (+)
and J-BspEI (−) were used to amplify the 50-half
fragments encompassing the SP6 promoter. The cDNA
product was digested with AscI and BspEI, and then
inserted into the AscI and BspEI sites of pACNR-L1.
Following transformation in competent E. coli MC1061
(Invitrogen), positive clones were selected and confirmed
by DNA sequencing and named as pANCR-JEV-5. The
30-1 and 30-2 fragments were obtained using the primer
Figure 3 Characterization of the JEV EGFP reporter replicons. BHK-21 cells were transfected with RNA transcripts from linearized pJ/GFP/
E3Rep, pJ/GFP/E25Rep and pJ/GFP/E71Rep, respectively and the expression of EGFP was observed under light and fluorescence microscopy at
the indicated time points post transfection.
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pairs of pBRJEV-7289(+), pBRJEV-7289(−) and pBRJEV-
7289-3U (+), pBRJEV-7289-3U (−), respectively. Both
fragments were first subcloned into pGEM-T-Easy vec-
tor (TaKaRa), yielding pT-3099-10976. The pT-3099
-10976 was then digested with BspEI and XhoI, and then
inserted into the pACNR-L1 to obtain the subclone cod-
ing the 30-half fragment and named pANCR-JEV-3.
Next, the JR-5-F (1 to 477) and JR-5-S (2468 to 2649)
fragments were amplified by RT-PCR using primer sets
F-AscI, R-J-Rep and F-J-Rep, R-J-BglII (introduced an-
other KasI site by a silent A to C substitution on pos-
ition 474 of C gene), and integrated together by
overlapping PCR to generate plasmid J-R-5 (ΔprM/E).
The J-R-5 (ΔprM/E) fragment was finally digested with
NotI and XhoI, and then ligated into the plasmid
pANCR-JEV-3, resulting into the desired JEV replicon
pJE3Rep. The constructed JEV replicon pJE3Rep lacks
the structural protein coding regions except for the
whole C protein and the last 3 amino acids of the E pro-
tein (Figure 1). It has been demonstrated that the coding
sequence of C protein was important in the RNA
cyclization and essential for the replication [29-31]. On
the other hand, the last three amino acids of the E pro-
tein were retained to ensure proper translocation of
the NS1 protein into the lumen of the endoplasmic
reticulum [12].
To assess whether the replicon was functional, the
plasmid pJE3Rep was linearized by digestion with the
XhoI restriction enzyme and then transcribed in vitro by
using the RiboMax™Large Scale RNA Production
system-sp6 Transcription Kit (Promega) in the presence
of the m7G (50) ppp (50)G cap analogs (Promega). The
in vitro synthesized RNAs were transfected into BHK-21
cells with Lipofectamine 2000 (Invitrogen) as previously
described [32]. Viral RNAs extracted from JEV infected
BHK-21 cells were transfected in the same way and used
as a positive control. PBS-transfected cells were used as
a negative control (Mock). To make sure whether viral
protein were successfully expressed by the replicon, the
transfected cells were fixed and analyzed by indirect im-
munofluorescence assay at 72 h post transfection using
monoclonal antibodies against E and NS1 proteins of
JEV, respectively. As shown in Figure 2A, the negative
control did not react with any of the antibodies, and
both NS1 and E proteins were detected in the viral
RNAs transfected cells. The replicon-transfected cells
only reacted with anti-NS1 monoclonal antibody, and no
E protein expression was noticed, indicating the JEV
replicon could express viral nonstructural protein. Add-
itionally, RT-PCR was carried out for the BHK-21 cells
using primers pair F2/R2 and F6/R6 targeting at the
prM/E and the NS3 genes. As expected, both genes were
detected in viral RNAs transfected cells (lane 3, 4), while
only the NS3 gene (lane 2) was detected in the JEV
replicon transfected cells. No PCR products were ampli-
fied for the mock transfected cells as expected (lane 5, 6).
These results demonstrated that the constructed JEV rep-
licon could efficiently replicate and express nonstructural
protein in transfected cells.
To further adapt the potential application of JEV repli-
con system, a series of JEV replicons expressing the
enhanced green fluorescent protein (EGFP) reporter gene
(Figure 1) were constructed. A DNA fragment encoding
2A protease of foot-and-mouth disease virus (FMDV-2A)
in fusion with the downstream region of the EGFP encod-
ing sequence was amplified from pEGFP-N1 vector
(Promega) using primer set F-KAS-EGFP and J-2A-E3-R.
The resulting fusion PCR fragment was digested by KasI
and BspEI and ligated into the pJE3Rep, yielding the JEV
reporter-replicon pJ/EGFP2A/E3Rep. Another two JEV
reporter-replicons retaining the C-terminal 25 and 71
amino acids residues of E protein, pJ/EGFP2A/E25Rep
and pJ/EGFP2A/E71Rep, respectively, were constructed.
All the molecular constructs were prepared by using
standard molecular biology techniques, and confirmed by
restriction digest analysis and DNA sequencing.
To measure the expression of EGFP reporter gene,
equal amounts of RNA transcripts derived from pJ/
EGFP2A/E3Rep, pJ/EGFP2A/E25Rep and pJ/EGFP2A/
E71Rep were transfected into BHK-21 cells. Transient
expression of EGFP in transfected cells was visualized
under light and fluorescence microscopy at 48, 72, 96
and 120 hours post transfection. As shown in Figure 3,
Figure 4 Characterization of the JEV R.Luc reporter replicon.
In vitro RNA transcripts of pJ/R.luc/E3Rep were transfected into BHK-
21 cells, and the cells were harvested at the indicated times post
transfection, the luciferase activity was measured by using a Glomax
system (Promega) according to the manufacturer’s instruction. The
results represent the means and standard deviations derived from
three independent experiments performed in triplicate.
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EGFP-positive cells were observed in all the replicon-
transfected BHK-21 cells, indicating that the reporter
gene was successfully expressed in the cells. An increase
of EGFP-positive cells could be observed in the early
time post transfection, indicating the success of self-
replication of the JEV replicon. Then, the EGFP-positive
cells began to reduce at about 120 h post transfection.
The EGFP-positive rate in the pJ/EGFP2A/E3Rep-
transfected cells was relatively higher than that in pJ/
EGFP2A/E25Rep- and pJ/EGFP2A/E71Rep-transfected
cells. And the pJ/EGFP2A/E71Rep replicon showed the
lowest positive rate among the three JEV replicons.
These results indicated that the remaining amino acid
length at the C-terminal of E protein could potentially
affect JEV replication. Additionally, no obvious cytotox-
icity was observed for all three replicons under light
microscope, which is in agreement with previous results
from YFV replicons [19]. Thus, all these JEV EGFP
reporter-replicons could replicate efficiently and express
EGFP proteins in BHK-21 cells.
Finally, the Renilla luciferase (R.luc) reporter JEV repli-
con, pJ/R.luc2A/E3Rep, was constructed using the same
strategy as the EGFP replicon (Figure 1) and the R.luc
gene was amplified from pRL-CMV vector (Promega).
To observe the expression of R.luc, in vitro RNA
transcripts of pJ/R.luc/E3Rep were transfected into
BHK-21 cells as previously described. For luciferase
assay, the transfected cells were lysed in 100 μl of pas-
sive lysis buffer (Promega) per well of a 48-well plate at
24, 48, 72, 96, 120 and 144 h post transfection, respect-
ively. Triplicate wells were seeded for each time point.
In general, luciferase activity assays were initiated by
mixing 20 μl of prepared cell extract with 100 μl of
the appropriate R.luc substrate, and then measured by
using a Glomax system (Promega) according to the
manufacturer’s instruction. The results showed that the
R.luc activity firstly peaked at 24 h post transfection,
then declined rapidly from the first peak. After that, the
R.luc activity began to rise stably until it reached a
second peak at 144 h post transfection (Figure 4).
Luciferase activity at early time points is indicative of
translation of the input replicon RNAs, while the second
peak at later time points represents proteins expressed by
newly synthesized RNAs [33]. Additionally, IFA and RT-
PCR assays also confirmed that the pJ/R.luc2A/E3Rep effi-
ciently expressed the NS1 proteins and synthesized viral
RNA of JEV at 72 h post transfection (data not shown).
These results indicated that this R.luc reporter JEV repli-
con could replicate efficiently and express R.luc proteins
in BHK-21 cells.
Previously, we have generated the infectious clone of
JEV and constructed mutant JEV by using reverse gen-
etic technology [34]. In this study, we have constructed a
series of JEV replicons based on the JEV live vaccine
strain SA14-14-2, and all these replicons are functionally
active to replicate and express the desired foreign re-
porter genes. These replicons constructed herein are
under the control of SP6 promoter. Previously, some
DNA-based JEV replicons that under the control of
CMV promoter have been developed and adapted for
pseudo infectious particles [35,36]. These JEV replicons
not only help to understand the molecular mechanism
of viral replication, but also provide a powerful tool for
foreign proteins expression, chimeric vaccine and single-
round virus like particles (VLP) based vaccine develop-
ment. The live vaccine virus SA14-14-2 has been widely
used in the most JEV endemic countries owing to its
highly efficiency, and very few adverse effects [37-39].
Another flavivirus live vaccine strain, YFV 17D, has been
widely used as genetic backbone for chimeric flavivirus
vaccine development [40-45]. The potential applications
of JEV SA14-14-2 in vaccine development are of high
significance and deserve further investigation [11,46,47].
Currently, we are working with these JEV replicons
to generate a series of chimeric flaviviruses vaccine
candidates.
Additional file
Additional file 1: Table S1. Oligonucleotide primers for construction of
JEV replicons and inserting reporter genes.
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